Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
How would you sequence treatment for HPV (+) concurrent advanced oropharynx and anal SCC?
Answer from: Radiation Oncologist at Academic Institution
Treat concomitantly.
Sign in or Register to read more
12781
Related Questions
How do you approach repeat SBRT in the abdomen, specifically when considering constraints for bowel and mesenteric vessels?
Would you offer liver re-irradiation in a Child-Pugh A patient with oligo-metastatic colon cancer to the liver, diagnosed > 10 years prior with previous TACE + SBRT to same liver metastasis ~5 years ago?
Are you using vaginal dilators during treatment of rectal cancer to spare anterior vaginal wall, or are you reserving this for anal cancers?
Is there data to support worse surgical outcomes in short course RT followed by surgery vs. long course chemoradiation followed by surgery in rectal cancer?
How would you approach unexpected chemo breaks during planned neoadjuvant chemoradiation for esophageal adenocarcinoma?
After R1 resection of a locally advanced, node-positive neuroendocrine tumor of the terminal ilium, would you offer adjuvant radiation therapy?
Would having mucinous rectal adenocarcinoma impact your recommendation for short vs long course RT as part of a TNT regimen?
Would you consider chemo-RT for duodenal adenocarcinoma s/p resection with at least 1 cm positive margin in a patient with a history of Crohn's disease?
Do you consider ablative radiation therapy for oligometastatic colon cancer with 5 pulmonary lesions responding to chemotherapy?
For a patient with T3N1M0 esophageal adenocarcinoma, who suffered esophageal perforation necessitating metallic stent placement, would you favor a neoadjuvant chemoradiation or perioperative chemotherapy approach?